Cancer researchers at Georgetown University Medical Center have taken a step towards understanding how and why a widely used chemotherapy drug works in patients with breast cancer.
A new class of targeted anti-cancer drugs that blocks the human epidermal growth factor (HER) receptor family shows promise in prolonging the lives of patients with recurrent prostate cancer, a new Cedars-Sinai study shows.
The North American Menopause Society in a revised position statement said that women taking hormone replacement therapy appear to be less likely to develop the diabetes disease.
Researchers at the University of Southern California (USC) recently made significant strides toward settling a decades-old debate centering on the role played by stem cells in cancer development. According to the study’s findings, which appear in an upcoming issue of Nature Genetics and now available online, genes that are reversibly repressed in embryonic stem cells are over-represented among genes that are permanently silenced in cancers; this link lends support to the increasingly discussed theory that cancer is rooted in small populations of stem cells.
Genentech, Inc. (NYSE: DNA) announced encouraging results from a randomized Phase II study comparing pertuzumab plus gemcitabine to gemcitabine alone in women with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer. Data from the study will be submitted for presentation at an upcoming medical meeting.
In 2005, the overall cost of patients’ time spent on cancer care was $2.3 billion in the first year after diagnosis, according to a new study in the Jan. 3 issue of the Journal of the National Cancer Institute. The time costs for the 11 cancers studied and for different phases of cancer care varied widely, they write.
A symptom survey may provide clinicians with a rapid, cost-effective screening tool to detect early stages of ovarian cancer, according to a new study.
Johns Hopkins scientists have discovered that women treated for ovarian cancer are at increased risk of a rapid and potentially fatal recurrence if their tumor cells have high levels of a binding protein that triggers abnormal growth and slows down cell death, both hallmarks of malignancy.
Scientists have discovered that induction of a gene known as MDA-7/IL-24 is the molecular mechanism that enables nonsteroidal anti-inflammatory drugs (NSAIDs) to halt the growth of cancer cells, a finding that could eventually lead to the development of targeted cancer treatments.
A symptom survey may provide clinicians with a rapid, cost-effective screening tool to detect early stages of ovarian cancer, according to a new study. The study reveals that early ovarian cancer may be distinguished from other causes by a specific set of symptoms and their frequency and duration.